(Q26851487)

language of work or name

1 reference

2013

1 reference

30 April 2013

6 references

13 March 2019

17 June 2019

7 November 2019

13 November 2019

17 November 2019

20 November 2019

7 references

13 March 2019

17 June 2019

7 November 2019

13 November 2019

17 November 2019

20 November 2019

10

1 reference

issue

4

1 reference

page(s)

e1001436

1 reference

Creative Commons Attribution 4.0 International

copyright license

6 references

13 March 2019

17 June 2019

7 November 2019

13 November 2019

17 November 2019

on focus list of Wikimedia project

20 November 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Phosphate binders for preventing and treating bone disease in chronic kidney disease patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Relation between kidney function, proteinuria, and adverse outcomes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Epidemiology of acute infections among patients with chronic kidney disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Effect of dialysis dose and membrane flux in maintenance hemodialysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

31 May 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

Association of activated vitamin D treatment and mortality in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001436

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

Parathyroidectomy rates among United States dialysis patients: 1990-1999.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640084

The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis

28 November 2018

1 reference

12 December 2020

Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients

1 reference

12 December 2020

A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism

1 reference

12 December 2020

Meta-analysis: vitamin D compounds in chronic kidney disease

1 reference

12 December 2020

Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients

1 reference

12 December 2020

10.1371/JOURNAL.PMED.1001436

Identifiers

DOI

1 reference

2071652

2071652

1 reference

1 reference

1 reference